Clinical Trial Update: Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating relebactam with imipenem/cilastatin versus imipenem/cilastatin alone for complicated intra-abdominal infection has completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intra-abdominal Infections

Drugs mentioned

• Imipenem/Cilastatin (imipenem/cilastatin)
• Relebactam + Imipenem/Cilastatin (relebactam)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Intra-abdominal Infections | Phase 2 | Status: COMPLETED | Results posted: 2019-06-10